EUVIMEDEUVIMED entdecken
Mixed-Methods-StudieOpen Access · CC BY-NC 4.0

Receiving a Pathogenic Variant in a Population Breast Cancer Screening Trial: A Mixed Method Study

Leslie Riddle, Jennifer Elyse James, Arash Naeim, Lisa Madlensky, Susie Brain, Diana DeRosa, Martin Eklund, Allison Stover Fiscalini, Diane Heditsian, Barbara Koenig, Katherine Ross, Leah P Sabacan und 3 weitere

Public Health Genomics · 2024

DOI: 10.1159/000540680 ↗

Kurz gefasst

Mixed-Methods-Studie in der Zeitschrift Public Health Genomics, 2024. Verfasst von Leslie Riddle und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Humanities and Social Sciences, UCSF, San Francisco, California, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Early Detection of Cancer, Genetic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Risk-based breast cancer screening aims to address persistent high morbidity and mortality. This study examined the experience of participants in the Women Informed to Screen Depending on Measures of Risk (WISDOM) trial who received a pathogenic variant in one of nine high or moderate penetrance breast cancer genes.

Methods

Participants completed a brief survey (n = 181) immediately following the results disclosure and 1 year later. Descriptive statistics were computed and comparisons between participants at different risk levels were performed using Fisher’s exact and McNemar’s tests. Analysis of qualitative interviews (n = 42) at 2–4 weeks and 6 months post-results disclosure compared responses at the 2 time points and explained and elaborated on the survey data.

Results

66.3% of survey respondents felt very or moderately prepared to receive genomic results. At the T1 survey, 80.7% of participants had shared the genetic result with a blood relative, increasing to 88.4% at T2; providing information and encouraging cascade testing were the most common reasons for sharing. Communication with a blood relative, other healthcare providers beyond the primary care provider, and cascade testing were higher for participants with a high risk than low or moderate risk genomic finding. Qualitative interviews elucidated varied reasons why participants felt (un)prepared for the results, including whether or not they had a family history of breast cancer, and illustrated the complexity of decision-making about sharing results.

Conclusions

Although most participants communicated results with family members and healthcare providers in accordance with their risk level, questions remain about how to adequately prepare individuals to receive pathogenic results, ensure timely and accessible follow-up care, and facilitate genetic counseling and cascade testing of at-risk relatives in the setting of population risk-based screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEarly Detection of CancerGenetic TestingHumansFemaleMiddle AgedAdultGenetic Predisposition to DiseaseSurveys and QuestionnairesAgedGenetic Counseling

Stichwörter der Autor:innen

Breast cancerEthics of genetic researchPopulation-based studiesPrecision Public Health

Autor:innen und Institutionen

  • Department of Humanities and Social Sciences, UCSF, San Francisco, California, USA.
  • Institute for Health and Aging, UCSF, San Francisco, California, USA.
  • Division of Hematology-Oncology, Center for SMART Health, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Moores Cancer Center, Family Cancer Genetics Program, University of California, San Diego, California, USA.
  • Breast Science Advocacy Core, University of California, San Francisco, California, USA.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.

Förderung

  • NCI NIH HHS

Zitieren

APA

Riddle, L., James, J. E., Naeim, A., Madlensky, L., Brain, S., DeRosa, D., Eklund, M., Fiscalini, A. S., Heditsian, D., Koenig, B., Ross, K., Sabacan, L. P., Tong, B., Wenger, N., & Joseph, G. (2024). Receiving a Pathogenic Variant in a Population Breast Cancer Screening Trial: A Mixed Method Study. Public Health Genomics. https://doi.org/10.1159/000540680

Vancouver

Riddle L, James JE, Naeim A, Madlensky L, Brain S, DeRosa D, et al. Receiving a Pathogenic Variant in a Population Breast Cancer Screening Trial: A Mixed Method Study. Public Health Genomics. 2024. doi:10.1159/000540680

BibTeX
@article{Riddle2024,
  author = {Riddle, Leslie and James, Jennifer Elyse and Naeim, Arash and Madlensky, Lisa and Brain, Susie and DeRosa, Diana and Eklund, Martin and Fiscalini, Allison Stover and Heditsian, Diane and Koenig, Barbara and Ross, Katherine and Sabacan, Leah P and Tong, Barry and Wenger, Neil and Joseph, Galen},
  title = {Receiving a Pathogenic Variant in a Population Breast Cancer Screening Trial: A Mixed Method Study},
  journal = {Public Health Genomics},
  year = {2024},
  doi = {10.1159/000540680}
}
Kostenlos starten →